What is the rationale for early intervention in high-risk smoldering MM?
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about the future perspectives for the treatment of patients with high-risk smoldering multiple myeloma (MM).
In this interview, Dr Kumar explored the emerging treatment landscape for high-risk smoldering MM, highlighting a shift from active monitoring to intervention. Kumar discussed the increasing evidence supporting early treatment in patients at high risk of progression to active MM, including data from clinical trials.
This educational resource is independently supported by Johnson & Johnson. All content…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.